In fact, in the present series, LOX expression was significantly lower among AGII (p = 0.049) and GBM (p = 0.008) cases presenting IDH1 mutations when compared to cases with wild-type IDH1. For GBM, a decreased level of LOX immunostaining in the nucleus was observed with the presence of IDH1 mutations. This evidence concerns the gene IDH1 and glioblastoma.